BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71:354-356. [PMID: 7841052 DOI: 10.1038/bjc.1995.71] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol 2016;143:40-5. [PMID: 27423378 DOI: 10.1016/j.ygyno.2016.07.103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Yeh KY, Li YY, Hsieh LL, Chen JR, Tang RP. The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan. J Clin Immunol 2010;30:53-9. [PMID: 19728052 DOI: 10.1007/s10875-009-9324-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
3 Chua W, Clarke SJ, Charles KA. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer 2012;20:1869-74. [PMID: 21986674 DOI: 10.1007/s00520-011-1289-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
4 Nagle CM, Ibiebele T, Shivappa N, Hébert JR, DeFazio A, Webb PM; Australian Ovarian Cancer Study. The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer. Eur J Nutr 2019;58:1747-56. [PMID: 30027314 DOI: 10.1007/s00394-018-1779-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256. [PMID: 24093089 DOI: 10.3389/fonc.2013.00256] [Cited by in Crossref: 199] [Cited by in F6Publishing: 207] [Article Influence: 24.9] [Reference Citation Analysis]
6 Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. International Review of Psychiatry 2014;26:16-30. [DOI: 10.3109/09540261.2013.875891] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 10.6] [Reference Citation Analysis]
7 Rath KS, Funk HM, Bowling MC, Richards WE, Drew AF. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol 2010;203:230.e1-8. [PMID: 20471626 DOI: 10.1016/j.ajog.2010.03.034] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
8 McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, Talpaz M, Neamati N, Buckanovich RJ. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene 2019;38:1576-84. [PMID: 30305729 DOI: 10.1038/s41388-018-0523-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
9 Bax HJ, Josephs DH, Pellizzari G, Spicer JF, Montes A, Karagiannis SN. Therapeutic targets and new directions for antibodies developed for ovarian cancer. MAbs 2016;8:1437-55. [PMID: 27494775 DOI: 10.1080/19420862.2016.1219005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
10 Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010;295:110-23. [PMID: 20236757 DOI: 10.1016/j.canlet.2010.02.019] [Cited by in Crossref: 136] [Cited by in F6Publishing: 132] [Article Influence: 12.4] [Reference Citation Analysis]
11 De Nola R, Menga A, Castegna A, Loizzi V, Ranieri G, Cicinelli E, Cormio G. The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication. Int J Mol Sci 2019;20:E2401. [PMID: 31096567 DOI: 10.3390/ijms20102401] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
12 Ind T, Iles R, Shepherd J, Chard T. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer-associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. BJOG:An international journal of O&G 1997;104:1024-9. [DOI: 10.1111/j.1471-0528.1997.tb12061.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.1] [Reference Citation Analysis]
13 [DOI: 10.1101/2020.02.11.944561] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lutgendorf SK, Costanzo ES, Siegel SD. Psychosocial Influences in Oncology: An Expanded Model of Biobehavioral Mechanisms. Psychoneuroimmunology. Elsevier; 2007. pp. 869-95. [DOI: 10.1016/b978-012088576-3/50048-4] [Cited by in Crossref: 10] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tangkijvanich P, Thong-ngam D, Mahachai V, Theamboonlers A, Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13(32): 4345-4349 [PMID: 17708609 DOI: 10.3748/wjg.v13.i32.4345] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
16 Gadducci A, Cosio S, Carpi A, Nicolini A, Genazza-ni AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother. 2004;58:24-38. [PMID: 14739059 DOI: 10.1016/j.biopha.2003.11.003] [Cited by in Crossref: 114] [Cited by in F6Publishing: 95] [Article Influence: 6.7] [Reference Citation Analysis]
17 Yutani S, Komatsu N, Matsueda S, Yoshitomi M, Shirahama T, Yamada A, Itoh K, Sasada T. Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine. Evid Based Complement Alternat Med 2013;2013:981717. [PMID: 23840274 DOI: 10.1155/2013/981717] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
18 Macciò A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review. J Mol Med (Berl) 2013;91:1355-68. [PMID: 24057813 DOI: 10.1007/s00109-013-1080-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
19 Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response. Curr Drug Targets 2020;21:996-1007. [PMID: 31994460 DOI: 10.2174/1389450121666200128161733] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Amin MN, Siddiqui SA, Ibrahim M, Hakim ML, Ahammed MS, Kabir A, Sultana F. Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer. SAGE Open Med 2020;8:2050312120965752. [PMID: 33194199 DOI: 10.1177/2050312120965752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
21 Farsinejad S, Cattabiani T, Muranen T, Iwanicki M. Ovarian Cancer Dissemination-A Cell Biologist's Perspective. Cancers (Basel) 2019;11:E1957. [PMID: 31817625 DOI: 10.3390/cancers11121957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Saeidi J, Motaghipur R, Sepehrian A, Mohtashami M, Forooghi Nia F, Ghasemi A. Dietary fats promote inflammation in Wistar rats as well as induce proliferation, invasion of SKOV3 ovarian cancer cells. J Food Biochem 2020;44:e13177. [PMID: 32157714 DOI: 10.1111/jfbc.13177] [Reference Citation Analysis]
23 Sawers L, Ferguson MJ, Ihrig BR, Young HC, Chakravarty P, Wolf CR, Smith G. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer 2014;111:1150-8. [PMID: 25010864 DOI: 10.1038/bjc.2014.386] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
24 Bhat IA, Qasim I, Masoodi KZ, Paul SA, Bhat BA, Rasool R, Aziz SA, Shah ZA. Significant impact of IL-6 -174G/C but inverse relation with -634 C/G polymorphism in patients with non-small cell lung cancer in Kashmiri population. Immunol Invest 2015;44:349-60. [PMID: 25942346 DOI: 10.3109/08820139.2015.1004336] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
25 Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003;83:222-226. [PMID: 12884234 DOI: 10.1002/jso.10269] [Cited by in Crossref: 211] [Cited by in F6Publishing: 200] [Article Influence: 11.7] [Reference Citation Analysis]
26 Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312-2316. [PMID: 15150588 DOI: 10.1038/sj.bjc.6601814] [Cited by in Crossref: 251] [Cited by in F6Publishing: 230] [Article Influence: 14.8] [Reference Citation Analysis]
27 Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol 2006;103:793-6. [PMID: 17023036 DOI: 10.1016/j.ygyno.2006.08.043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
28 Leung F, Diamandis EP, Kulasingam V. Ovarian Cancer Biomarkers. Elsevier; 2014. pp. 25-77. [DOI: 10.1016/b978-0-12-801401-1.00002-5] [Cited by in Crossref: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Younes G, Segev Y, Begal J, Auslender R, Goldberg Y, Amit A, Lavie O. The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC). European Journal of Obstetrics & Gynecology and Reproductive Biology 2016;199:16-20. [DOI: 10.1016/j.ejogrb.2016.01.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
30 Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev 2015;34:19-40. [PMID: 25544368 DOI: 10.1007/s10555-014-9538-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
31 Masoumi H, Soltani A, Ghatrehsamani M. The beneficial role of SIRT1 activator on chemo- and radiosensitization of breast cancer cells in response to IL-6. Mol Biol Rep 2020;47:129-39. [PMID: 31781916 DOI: 10.1007/s11033-019-05114-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 2009;113:21-7. [PMID: 19162309 DOI: 10.1016/j.ygyno.2008.12.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
33 Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, Wagner U, Müller-Brüsselbach S, Reinartz S, Müller R. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics 2017;18:243. [PMID: 28327095 DOI: 10.1186/s12864-017-3630-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
34 Purcell SA, Elliott SA, Kroenke CH, Sawyer MB, Prado CM. Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis. Curr Oncol Rep 2016;18:8. [PMID: 26769113 DOI: 10.1007/s11912-015-0488-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
35 Sturgeon CM, Duffy MJ, Stenman U, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih I, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clinical Chemistry 2008;54:e11-79. [DOI: 10.1373/clinchem.2008.105601] [Cited by in Crossref: 395] [Cited by in F6Publishing: 328] [Article Influence: 30.4] [Reference Citation Analysis]
36 Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250-255. [PMID: 11937016 DOI: 10.1007/s11912-002-0023-1] [Cited by in Crossref: 205] [Cited by in F6Publishing: 185] [Article Influence: 10.8] [Reference Citation Analysis]
37 Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, Yang H, Feng M, Xuan Y, Yang Y, Lei L, Wang C, Yi T, Zhao X, Wei Y, Zhou S. Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Letters 2016;377:174-82. [DOI: 10.1016/j.canlet.2016.04.038] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 16.2] [Reference Citation Analysis]
38 Ibrahim AS, Farrag WS, Galal Aly M. Ultrasound guided bilateral rectus sheath block and serum TNF-α and IL-6 after radical prostatectomy: A randomized double blinded study. Egyptian Journal of Anaesthesia 2019;34:139-43. [DOI: 10.1016/j.egja.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Yoshida M, Taguchi A, Kawana K, Ogishima J, Adachi K, Kawata A, Nakamura H, Sato M, Fujimoto A, Inoue T, Tomio K, Mori M, Nagamatsu T, Arimoto T, Koga K, Hiraike OW, Oda K, Kiyono T, Osuga Y, Fujii T. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity. Int J Oncol 2018;53:1580-90. [PMID: 30066851 DOI: 10.3892/ijo.2018.4504] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
40 Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine 2015;73:108-13. [PMID: 25743245 DOI: 10.1016/j.cyto.2015.01.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
41 Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, Isidoro C. Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy. Mol Carcinog 2017;56:1164-81. [PMID: 27787915 DOI: 10.1002/mc.22582] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
42 Lutgendorf SK, Anderson B, Sorosky JI, Buller RE, Lubaroff DM. Interleukin-6 and use of social support in gynecologic cancer patients. Int J Behav Med 2000;7:127-42. [DOI: 10.1207/s15327558ijbm0702_3] [Cited by in Crossref: 40] [Article Influence: 1.9] [Reference Citation Analysis]
43 Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97. [PMID: 11775462 DOI: 10.1007/978-1-4757-3587-1_3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 4.5] [Reference Citation Analysis]
44 Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piché A. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492. [PMID: 26122176 DOI: 10.1186/s12885-015-1511-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
45 Andrews B, Shariat SF, Kim J, Wheeler TM, Slawin KM, Lerner SP. PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. Journal of Urology 2002;167:1475-81. [DOI: 10.1016/s0022-5347(05)65348-7] [Cited by in Crossref: 68] [Article Influence: 3.6] [Reference Citation Analysis]
46 Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, Goodheart MJ, Dahmoush L, Penedo F, Lucci JA 3rd, Ganjei-Azar P, Mendez L, Markon K, Lubaroff DM, Thaker PH, Slavich GM, Sood AK, Lutgendorf SK. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav Immun 2013;30 Suppl:S126-34. [PMID: 22884960 DOI: 10.1016/j.bbi.2012.07.022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
47 Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012;58:133-47. [PMID: 22349527 DOI: 10.1016/j.cyto.2012.01.015] [Cited by in Crossref: 159] [Cited by in F6Publishing: 150] [Article Influence: 17.7] [Reference Citation Analysis]
48 Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E, Ghanim B. Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation. Cancers (Basel) 2021;13:658. [PMID: 33562138 DOI: 10.3390/cancers13040658] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013;12:26. [PMID: 23561329 DOI: 10.1186/1476-4598-12-26] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 10.3] [Reference Citation Analysis]
50 Noh KW, Pungpapong S, Wallace MB, Woodward TA, Raimondo M. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol. 2006;4:782-789. [PMID: 16713745 DOI: 10.1016/j.cgh.2006.03.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
51 Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev 2014;33:17-39. [PMID: 24357056 DOI: 10.1007/s10555-013-9456-2] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 17.3] [Reference Citation Analysis]
52 Nguyen L, Cardenas-Goicoechea SJ, Gordon P, Curtin C, Momeni M, Chuang L, Fishman D. Biomarkers for early detection of ovarian cancer. Womens Health (Lond). 2013;9:171-185; quiz 186-187. [PMID: 23477323 DOI: 10.2217/whe.13.2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
53 Scambia G, Foti E, Ferrrandina G, Leone FP, Gadducci A, Benedetti-panici P, Mancuso S. Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. American Journal of Obstetrics and Gynecology 1996;175:1606-10. [DOI: 10.1016/s0002-9378(96)70113-8] [Cited by in Crossref: 8] [Article Influence: 0.3] [Reference Citation Analysis]
54 Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral influences on cancer progression. Immunol Allergy Clin North Am 2011;31:109-32. [PMID: 21094927 DOI: 10.1016/j.iac.2010.09.001] [Cited by in Crossref: 68] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
55 Giridhar PV, Funk HM, Gallo CA, Porollo A, Mercer CA, Plas DR, Drew AF. Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells. Clin Exp Metastasis 2011;28:887-97. [DOI: 10.1007/s10585-011-9420-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
56 Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev. 2008;222:101-116. [PMID: 18363996 DOI: 10.1111/j.1600-065x.2008.00614.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 56] [Article Influence: 9.1] [Reference Citation Analysis]
57 Nesseler JP, Schaue D, McBride WH, Nickers P. [Inflammatory and immune biomarkers of radiation response]. Cancer Radiother 2018;22:180-92. [PMID: 29650389 DOI: 10.1016/j.canrad.2017.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Wen W, Han ES, Dellinger TH, Wu J, Guo Y, Buettner R, Horne DA, Jove R, Yim JH. Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer. Transl Oncol 2019;12:1015-25. [PMID: 31141756 DOI: 10.1016/j.tranon.2019.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
59 Gyorffy B, Lánczky A, Szállási Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012;19:197-208. [PMID: 22277193 DOI: 10.1530/ERC-11-0329] [Cited by in Crossref: 446] [Cited by in F6Publishing: 386] [Article Influence: 49.6] [Reference Citation Analysis]
60 Wang LS, Chow KC, Wu CW. Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate. Br J Cancer 1999;80:1617-22. [PMID: 10408408 DOI: 10.1038/sj.bjc.6690571] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 1.8] [Reference Citation Analysis]
61 Shi Z, Yang W, Chen L, Yang D, Zhou Q, Zhu J, Chen J, Huang R, Chen Z, Huang R. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treat 2012;135:737-47. [DOI: 10.1007/s10549-012-2196-0] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
62 So KA, Hong JH, Jin HM, Kim JW, Song JY, Lee JK, Lee NW. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study. Gynecol Oncol 2014;132:551-5. [PMID: 24440470 DOI: 10.1016/j.ygyno.2014.01.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
63 Tran AQ, Cohen JG, Li AJ. Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer. Gynecol Oncol 2015;138:263-6. [PMID: 26037901 DOI: 10.1016/j.ygyno.2015.05.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
64 Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, Okuda H, Kudo T. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;82:107-10. [PMID: 10192497 DOI: 10.1016/s0301-2115(98)00227-9] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
65 Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H; Cancer and Leukemia Group B. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat 2006;100:301-8. [PMID: 16773437 DOI: 10.1007/s10549-006-9251-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
66 Kacel EL, Kirsch JL, Sannes TS, Patidar S, Postupack R, Jensen S, Wong S, Garey S, Dodd S, Ulfig CM, McCrae CS, Robinson ME, Castagno J, Schultz GS, Pereira DB. Interleukin-6 and body mass index, tobacco use, and sleep in gynecologic cancers. Health Psychol 2019;38:866-77. [PMID: 31368718 DOI: 10.1037/hea0000775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets 2013;17:1303-28. [DOI: 10.1517/14728222.2013.830105] [Cited by in Crossref: 39] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
68 Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794-8. [PMID: 9470835 DOI: 10.1016/s0959-8049(97)00179-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
69 Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 2012;118:3208-21. [PMID: 22071976 DOI: 10.1002/cncr.26636] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
70 Xu S, Yu C, Ma X, Li Y, Shen Y, Chen Y, Huang S, Zhang T, Deng W, Wang Y. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells. Eur J Pharmacol 2021;894:173817. [PMID: 33345849 DOI: 10.1016/j.ejphar.2020.173817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
71 Macciò A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005;106:362-7. [PMID: 15774616 DOI: 10.1182/blood-2005-01-0160] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
72 Balkwill FR, Mantovani A. Cancer-related inflammation: Common themes and therapeutic opportunities. Seminars in Cancer Biology 2012;22:33-40. [DOI: 10.1016/j.semcancer.2011.12.005] [Cited by in Crossref: 406] [Cited by in F6Publishing: 371] [Article Influence: 45.1] [Reference Citation Analysis]
73 Huang J, Hu W, Sood AK. Prognostic biomarkers in ovarian cancer. Cancer Biomark 2010-2011;8:231-51. [PMID: 22045356 DOI: 10.3233/CBM-2011-0212] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
74 Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring. J Ovarian Res 2015;8:58. [PMID: 26282935 DOI: 10.1186/s13048-015-0183-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
75 Al-Wahab Z, Mert I, Tebbe C, Chhina J, Hijaz M, Morris RT, Ali-Fehmi R, Giri S, Munkarah AR, Rattan R. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction. Oncotarget 2015;6:10908-23. [PMID: 25895126 DOI: 10.18632/oncotarget.3434] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
76 Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton SE, Rohleder N, Lucci JA 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008;26:4820-7. [PMID: 18779606 DOI: 10.1200/JCO.2007.14.1978] [Cited by in Crossref: 125] [Cited by in F6Publishing: 76] [Article Influence: 9.6] [Reference Citation Analysis]
77 Taher MY, Davies DM, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochem Soc Trans 2018;46:1449-62. [PMID: 30467123 DOI: 10.1042/BST20180136] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
78 Lippitz BE, Harris RA. Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5:e1093722. [PMID: 27467926 DOI: 10.1080/2162402x.2015.1093722] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 17.4] [Reference Citation Analysis]
79 Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005;104:305-13. [DOI: 10.1002/cncr.21147] [Cited by in Crossref: 140] [Cited by in F6Publishing: 128] [Article Influence: 8.8] [Reference Citation Analysis]
80 Li YY, Chang JW, Hsieh LL, Yeh KY. Neutralization of interleukin (IL)-10 released by monocytes/macrophages enhances the up-regulatory effect of monocyte/macrophage-derived IL-6 on expressions of IL-6 and MUC1, and migration in HT-29 colon cancer cells. Cell Immunol. 2010;265:164-171. [PMID: 20851386 DOI: 10.1016/j.cellimm.2010.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
81 Liu X, Li M, Li W, Wang Q, Zhang H. Combined Effect of Lentinan and Cisplatin on Cytokines IL-6, TNF- α , and TGF- β in Tumor Therapy. International Journal of Polymer Science 2019;2019:1-11. [DOI: 10.1155/2019/4064703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther. 2010;87:401-406. [PMID: 20200512 DOI: 10.1038/clpt.2009.312] [Cited by in Crossref: 172] [Cited by in F6Publishing: 165] [Article Influence: 15.6] [Reference Citation Analysis]
83 Seymour JF, Kurzrock R. Interleukin-6: biologic properties and role in lymphoproliferative disorders. In: Freireich EJ, Kantarjian H, editors. Molecular Genetics and Therapy of Leukemia. Boston: Springer US; 1996. pp. 167-206. [DOI: 10.1007/978-1-4613-1261-1_9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
84 Zhou Y, Irwin ML, Risch HA. Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality. Gynecol Oncol 2011;120:209-13. [PMID: 21106231 DOI: 10.1016/j.ygyno.2010.10.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ramos RN, de Moraes CJ, Zelante B, Barbuto JA. What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clin Dev Immunol 2013;2013:806025. [PMID: 23762097 DOI: 10.1155/2013/806025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
86 Kim S, Hagemann A, DeMichele A. Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer. Immunol Invest 2009;38:324-40. [PMID: 19811442 DOI: 10.1080/08820130902910567] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
87 Chen MF, Lin PY, Wu CF, Chen WC, Wu CT. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 2013;8:e61901. [PMID: 23637926 DOI: 10.1371/journal.pone.0061901] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
88 Yousefi H, Momeny M, Ghaffari SH, Parsanejad N, Poursheikhani A, Javadikooshesh S, Zarrinrad G, Esmaeili F, Alishahi Z, Sabourinejad Z, Sankanian G, Shamsaiegahkani S, Bashash D, Shahsavani N, Tavakkoly-bazzaz J, Alimoghaddam K, Ghavamzadeh A. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer. Tumori 2019;105:84-91. [DOI: 10.1177/0300891618784790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
89 Lee JJ, Kim HJ, Yang CS, Kyeong HH, Choi JM, Hwang DE, Yuk JM, Park K, Kim YJ, Lee SG, Kim D, Jo EK, Cheong HK, Kim HS. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther 2014;22:1254-65. [PMID: 24682171 DOI: 10.1038/mt.2014.59] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
90 Di Nisio M, Niers TM, Reitsma PH, Buller HR. Plasma cytokine and P-selectin levels in advanced malignancy: Prognostic value and impact of low-molecular weight heparin administration. Cancer 2005;104:2275-81. [DOI: 10.1002/cncr.21485] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
91 Finkernagel F, Reinartz S, Schuldner M, Malz A, Jansen JM, Wagner U, Worzfeld T, Graumann J, von Strandmann EP, Müller R. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. Theranostics 2019;9:6601-17. [PMID: 31588238 DOI: 10.7150/thno.37549] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
92 Reichner JS, Mulligan JA, Spisni R, Sotomayor EA, Albina JE, Bland KI. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol 1998;5:279-86. [PMID: 9607632 DOI: 10.1007/BF02303786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
93 Gücer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998;70:210-4. [PMID: 9740692 DOI: 10.1006/gyno.1998.5078] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
94 Jiang XP, Yang DC, Elliott RL, Head JF. Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine 2000;12:458-65. [PMID: 10857759 DOI: 10.1006/cyto.1999.0591] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
95 Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN; and the ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Results from the ASCENT trial. Cancer 2008;112:2377-83. [DOI: 10.1002/cncr.23461] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
96 Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011;9:18. [PMID: 21294915 DOI: 10.1186/1477-7819-9-18] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
97 Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012;59:228-36. [PMID: 22595649 DOI: 10.1016/j.cyto.2012.04.020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
98 Cândido EB, Silva LM, Carvalho AT, Lamaita RM, Filho RM, Cota BD, da Silva-Filho AL. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci 2013;20:828-37. [PMID: 23239818 DOI: 10.1177/1933719112466299] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
99 Macciò A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69:248-252. [PMID: 9648596 DOI: 10.1006/gyno.1998.4974] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 2.6] [Reference Citation Analysis]
100 Gadducci A, Cosio S, Tana R, Genazzani AR. Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol 2009;69:12-27. [PMID: 18595727 DOI: 10.1016/j.critrevonc.2008.05.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
101 Savant SS, Sriramkumar S, O'Hagan HM. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. Cancers (Basel) 2018;10:E251. [PMID: 30061485 DOI: 10.3390/cancers10080251] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
102 Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S, Müller R. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 2014;134:32-42. [PMID: 23784932 DOI: 10.1002/ijc.28335] [Cited by in Crossref: 136] [Cited by in F6Publishing: 136] [Article Influence: 17.0] [Reference Citation Analysis]
103 Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;17:6083-96. [PMID: 21795409 DOI: 10.1158/1078-0432.CCR-11-0945] [Cited by in Crossref: 248] [Cited by in F6Publishing: 151] [Article Influence: 24.8] [Reference Citation Analysis]
104 Ye Q, Wu Z, Xia T, Liu D, Yang Y, Tang H. Pre-treatment thrombocytosis predicts prognosis of endometrial cancer: A meta-analysis of 11 studies. Exp Ther Med 2020;19:359-66. [PMID: 31853312 DOI: 10.3892/etm.2019.8205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
105 Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Müller R. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol 2017;7:24. [PMID: 28275576 DOI: 10.3389/fonc.2017.00024] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 23.8] [Reference Citation Analysis]
106 Clinchy B, Fransson A, Druvefors B, Hellsten A, Håkansson A, Gustafsson B, Sjödahl R, Håkansson L. Preoperative interleukin-6 production by mononuclear blood cells predicts survival after radical surgery for colorectal carcinoma. Cancer 2007;109:1742-9. [PMID: 17345614 DOI: 10.1002/cncr.22623] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
107 Duan Z, Lamendola D, Penson R, Kronish K, Seiden M. OVEREXPRESSION OF IL-6 BUT NOT IL-8 INCREASES PACLITAXEL RESISTANCE OF U-2OS HUMAN OSTEOSARCOMA CELLS. Cytokine 2002;17:234-42. [DOI: 10.1006/cyto.2001.1008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
108 Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, Macneill KM, Matulonis UA, Preffer FI, Seiden MV. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41. [DOI: 10.1046/j.1525-1438.2000.00003.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 108] [Article Influence: 5.6] [Reference Citation Analysis]
109 Isobe A, Sawada K, Kinose Y, Ohyagi-Hara C, Nakatsuka E, Makino H, Ogura T, Mizuno T, Suzuki N, Morii E, Nakamura K, Sawada I, Toda A, Hashimoto K, Mabuchi S, Ohta T, Morishige K, Kurachi H, Kimura T. Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS One 2015;10:e0118080. [PMID: 25658637 DOI: 10.1371/journal.pone.0118080] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
110 Bonilla L, Oza A, Lheureux S. Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opin Emerg Drugs 2018;23:1-16. [PMID: 29528256 DOI: 10.1080/14728214.2018.1446942] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-910. [PMID: 22651903 DOI: 10.1016/j.ctrv.2012.04.007] [Cited by in Crossref: 401] [Cited by in F6Publishing: 402] [Article Influence: 44.6] [Reference Citation Analysis]
112 Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo A, Basolo F. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 1999;80:579-84. [PMID: 10408869 DOI: 10.1038/sj.bjc.6690394] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
113 Gadducci A, Cosio S, Zanca G, Genazzani AR. Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer. Womens Health (Lond Engl) 2006;2:141-58. [DOI: 10.2217/17455057.2.1.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
114 Albeniz I, Demir O, Türker-Sener L, Yalçintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. Hematology 2007;12:409-14. [PMID: 17852458 DOI: 10.1080/10245330701383841] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
115 Grimm C, Six L, Tomovski C, Speiser P, Joura E, Zeillinger R, Sliutz G, Reinthaller A, Hefler LA. A Common Interleukin-6 Promoter Polymorphism in Patients With Vulvar Cancer. Journal of the Society for Gynecologic Investigation 2016;12:617-20. [DOI: 10.1016/j.jsgi.2005.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
116 Sancéau J, Kaisho T, Hirano T, Wietzerbin J. Triggering of the Human Interleukin-6 Gene by Interferon-γ and Tumor Necrosis Factor-α in Monocytic Cells Involves Cooperation between Interferon Regulatory Factor-1, NFκB, and Sp1 Transcription Factors. Journal of Biological Chemistry 1995;270:27920-31. [DOI: 10.1074/jbc.270.46.27920] [Cited by in Crossref: 158] [Cited by in F6Publishing: 151] [Article Influence: 6.1] [Reference Citation Analysis]
117 Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells – An updated review. Experimental Cell Research 2018;362:1-10. [DOI: 10.1016/j.yexcr.2017.10.018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 16.3] [Reference Citation Analysis]
118 Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Interleukin-6 (IL-6) released by macrophages induces IL-6 secretion in the human colon cancer HT-29 cell line. Hum Immunol. 2009;70:151-158. [PMID: 19272324 DOI: 10.1016/j.humimm.2009.01.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
119 Subedi P, Gomolka M, Moertl S, Dietz A. Ionizing Radiation Protein Biomarkers in Normal Tissue and Their Correlation to Radiosensitivity: A Systematic Review. J Pers Med 2021;11:140. [PMID: 33669522 DOI: 10.3390/jpm11020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Lowery WJ, Stany MP, Phippen NT, Bunch KP, Oliver KE, Tian C, Maxwell GL, Darcy KM, Hamilton CA. Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: A Surveillance, Epidemiology and End Results study. Gynecologic Oncology 2015;136:328-35. [DOI: 10.1016/j.ygyno.2014.12.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
121 Ray-Coquard I. Biology of ovarian cancer and trabectedin mechanism of action. Future Oncol 2013;9:11-7. [PMID: 24195525 DOI: 10.2217/fon.13.199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
122 Lutgendorf SK, Thaker PH, Arevalo JM, Goodheart MJ, Slavich GM, Sood AK, Cole SW. Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer 2018;124:580-6. [PMID: 29112229 DOI: 10.1002/cncr.31078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
123 Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005;98:92-8. [DOI: 10.1016/j.ygyno.2005.03.016] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
124 Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, Horne D, Morgan R, Wakabayashi M, Dellinger TH, Han ES, Yim JH, Jove R. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther 2014;13:3037-48. [PMID: 25319391 DOI: 10.1158/1535-7163.MCT-14-0077] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
125 Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011;11:210. [PMID: 21619709 DOI: 10.1186/1471-2407-11-210] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 9.6] [Reference Citation Analysis]
126 Sotelo JL, Nemeroff CB. Depression as a systemic disease. Personalized Medicine in Psychiatry 2017;1-2:11-25. [DOI: 10.1016/j.pmip.2016.11.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
127 Woolery KT, Kruk PA. Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. Obstet Gynecol Int 2011;2011:358493. [PMID: 21765834 DOI: 10.1155/2011/358493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
128 Diaz ES, Karlan BY, Li AJ. Obesity-associated adipokines correlate with survival in epithelial ovarian cancer. Gynecol Oncol 2013;129:353-7. [PMID: 23402904 DOI: 10.1016/j.ygyno.2013.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
129 Yoshitomi M, Yutani S, Matsueda S, Ioji T, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kinoshita H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med 2012;3:463-9. [PMID: 22969912 DOI: 10.3892/etm.2011.424] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
130 Kumar J, Ward AC. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications. Biochim Biophys Acta 2014;1845:117-25. [PMID: 24388871 DOI: 10.1016/j.bbcan.2013.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis]
131 Coward JI, Kulbe H. The role of interleukin-6 in gynaecological malignancies. Cytokine & Growth Factor Reviews 2012;23:333-42. [DOI: 10.1016/j.cytogfr.2012.08.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]